Literature DB >> 23281516

Malignancies of the spinal cord.

J Dawn Waters1, Encarnacion Maria Navarro Peran, Joseph Ciacci.   

Abstract

The management of intramedullary spinal cord tumors (IMSCT) is primarily concerned with the preservation of existing neurologic function. To this end, clinical scientists are continually seeking tools and techniques to improve the safety and efficacy of tumor resection and control. Further advances in safety and efficacy can be proposed at each phase of management, from pre-operative screening to post-treatment monitoring. Innovations within the areas of molecular biology and genetics, intraoperative imaging and stereotactic radiosurgery offer exciting new options to explore in the management of IMSCT. This section will review the pathophysiology and epidemiology of IMSCT and the state-of-the-art management before delving into the promising new tools and techniques for each phase of management.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23281516     DOI: 10.1007/978-1-4614-4090-1_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Spinal perimedullary vein enlargement sign: an added value for the differentiation between intradural-extramedullary and intramedullary tumors on magnetic resonance imaging.

Authors:  Tao Gong; Yubo Liu; Guangbin Wang; Li Yang; Weibo Chen; Fei Gao; Xin Chen
Journal:  Neuroradiology       Date:  2016-09-05       Impact factor: 2.804

2.  Variation in management of spinal gliobastoma multiforme: results from a national cancer registry.

Authors:  F M Moinuddin; Mohammed Ali Alvi; Panagiotis Kerezoudis; Waseem Wahood; Jenna Meyer; Daniel Honore Lachance; Mohamad Bydon
Journal:  J Neurooncol       Date:  2018-11-20       Impact factor: 4.130

3.  Primary spinal glioblastoma multiforme: A case report and review of the literature.

Authors:  Chao-Xiong Shen; Jian-Feng Wu; Wei Zhao; Zhao-Wen Cai; Ran-Ze Cai; Chun-Mei Chen
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.